EVOK News and Press, Evoke Pharma Inc. From 06/15/21

Evoke Pharma (EVOK) announces positive findings from a second market research study conducted for GIMOTI (metoclopramide) nasal spray.The study aimed to gather further market insights on perception of GIMOTI in the GI community. In May 2021, Evoke’s commercialization partner, EVER...

SOLANA BEACH, Calif. and CHICAGO, June 15, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, and EVERSANA™, a leading provider of global commercial services to the life science indu...

Evoke Pharma (EVOK) jumps 8.4% premarket in reaction to the announcement that its US patent No. 11,020,361 for Gimoti (metoclopramide) nasal spray is now listed in the FDA's “Orange Book”.The patent covers methods of use for nasal delivery of metoclopramide for th...

SOLANA BEACH, Calif., June 08, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that its US patent No. 11,020,361 for Gimoti ® (metoclopramide) nasal spray is now...

Evoke Pharma (EVOK) announces that the United States Patent and Trademark Office ((USPTO)) has issued US patent no. 11,020,361 to the company related to Gimoti (metoclopramide) nasal spray. The patent covers methods of use for nasal delivery of metoclopramide for the treatment of ga...

New patent expands intellectual property protection for nasal delivery of metoclopramide and is expected to be FDA Orange Book listed SOLANA BEACH, Calif., June 02, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments...

Evoke is committed to meeting patients online, where they search for answers New campaign leverages Facebook to satisfy significant unmet need for education and community SOLANA BEACH, Calif. and CHICAGO, May 27, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a ...

The stock price has been decimated after a sluggish commercial launch for Gimoti. COVID is not likely the only problem. The January funding will not be enough - Evoke will need to raise $20 mil to $60 mil to get to cash flow positive. The best outcome for current investors is prob...

Evoke Pharma (EVOK) announces the appointment of Vickie Reed to the company’s board of directors.The appointment follows the retirement of Ann Rhoads from the company's board after a tenure of more than eight years.Reed currently serves as Senior Vice President, Fin...

SOLANA BEACH, Calif., May 14, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced the appointment of Vickie Reed to the Company’s board of directors. After serving for...